On the move

CurrentPartnering's On The Move feature lists details of business development executives who have recently moved roles or companies, enabling peers to keep pace with career movements.

March 2010

Dale Trask, Vice President Global Business Development

To: Venn Life Sciences From: Excel PharmaStudies

Dale Trask brings extensive experience in Clinical Research Organisation business development and will be responsible for enhancing Venn’s business partnerships, strategic relationships and growth into new markets.

Alun Malone, New Business Development Executive

To: Millennium Laboratories From: unknown

Alun Malone will be responsible for business development and implementing strategic initiatives, and will report to Howard Appel, President of Millennium Laboratories.

Carmine Stengone, Vice President Corporate Development

To: Afraxis From: unknown

Carmine Stengone's business savvy make them uniquely suited for achieving the objectives of Afraxis.

Yvonne Verburgt, Vice President Business Development and Marketing

To: Avrio Biopharmaceuticals LLC From: Pharmatek Laboratories, Inc.

Yvonne Verburgt brings over 28 years of pharmaceutical industry experience to the company and to the clients it serves.

Molly McGlaughlin, Vice President of Sales & Business Development – International

To: Cytovance Biologics LLC From: promotion

Molly McGlaughlin and her team were responsible for the robust revenue growth through securing custom-designed development and manufacturing agreements with numerous clients.

William Dull, Vice President of Sales & Business Development – North America

To: Cytovance Biologics LLC From: Genentech

William Dull will be responsible for Cytovance’s business development activities in North America, including the marketing and sales.

Terry Nida, Chief Business Officer

To: Transdel Pharmaceuticals, Inc. From: Executive Consultant for pharmaceutical and biotechnology companies

Terry Nida has developed an established and successful track record in negotiating and closing global and regional joint development, licensing, distribution, sales and marketing partnerships and supply agreements with multiple pharmaceutical companies.

February 2010

Barbara Goldsmith, Vice President Marketing and Business Development

To: Clinical and Laboratory Standards Institute From: Caritas Christi Health Care

Barbara Goldsmith will oversee the development and implementation of new business development and marketing strategies and programs that build CLSI's visibility and leadership, and support the organization's mission, strategic plan priorities, and brand value.

Robert Phelps, Head Business Development & Licensing

To: SuppreMol GmbH From: PARI Pharma GmbH

Robert Phelps has held business development and licensing positions at various biotechnology and pharmaceutical companies such as Bavarian Nordic A/S, Patheon UK Ltd., Evotec AG, and Hexal Gentech ForschungsGmbH.

Michael Markels, Vice President, Commercial Operations and Business Development

To: NeurogesX, Inc. From: promotion

Michael Markels has 18 years experience in domestic and international sales, strategic marketing and drug development.

David Poorvin, Chief Business Officer

To: Avaxia Biologics, Inc. From: Oxford Bioscience Partners

David Poorvin will be responsible for leading the Company's business development activities.

Patrick Gallagher, Vice President of Business Development

To: Noven Pharmaceuticals, Inc. From: Acusphere

Patrick Gallagher has over 25 years' experience in the pharmaceutical, biotechnology and drug delivery industries.

Nigel Clark, Chief Business Officer

To: Syntaxin From: Vernalis

Nigel Clark has a strong track record in building strategic alliances, including business development leadership roles with Ribotargets and British Biotech.

January 2010

Lauren Sabella, Executive Vice President Commercial Development

To: Acorda Therapeutics, Inc. From: Tugboat Consulting Group

Lauren Sabella will have responsibility for Acorda’s commercial operations, including marketing, sales and managed markets.

Brant Biehn, Chief Commercial Development Officer

To: Dynavax Technologies From: Merck

Brnat Biehn will be responsible for the development and execution of Dynavax's commercial strategy, including market development, sales, and distribution channel partnerships.

Zachary Zimmerman, Director Business Development

To: Regulus Therapeutics Inc. From: Alnylam Pharmaceuticals

Zachary Zimmerman will be responsible for business development and licensing, as well as managing external collaborations and communications.

Francesco Granata, Executive Vice President of Global Commercial Operations

To: Biogen Idec From: Schering-Plough

Francesco Granata has more than 30 years of experience developing and successfully executing global commercial business strategies and leading significant biotech and pharmaceutical organizations.

Kerry Reinertsen, Chief Business Officer

To: Constellation Pharmaceuticals, Inc. From: Vertex Pharmaceuticals

Kerry Reinertsen will manage Constellation’s corporate and business development activities, including the formation, implementation and management of research and development alliances to maximize value creation from its significant set of R&D assets.

Jeffrey Paulsen, Group President, Global Businesses

To: Zimmer Holdings, Inc. From: MPS Group Inc.

Jeffrey Paulsen will have responsibility for Zimmer Spine, Zimmer Dental, Zimmer Trauma and Zimmer Orthopaedic Surgical Products.

Art Ziegler, Vice President Business Development

To: Prologue Research International From: Smithkline & French Laboratories

Art Ziegler primary roles will include securing levels of sustainable, profitable revenue necessary to meet the company's financial objectives through effective sales and marketing strategies, developing and implementing marketing and sales initiatives to create awareness and demand for Prologue services within the oncology clinical research community and identifying, and meeting key decision makers of potential clients.

Tim Hanke, Vice President Commercial Operations

To: BioVex Inc. From: Genta

Tim Hanke will be responsible for preparing for the commercialization of BioVex’s investigational product, OncoVEX.

Note:

Some links may expire. Whilst we endeavour to remove any deleted links, some may occur outside our control. If you find a deleted link please let us know.